BR112017003010A2 - (2s)-3-[(3s,4s)-3-[(1r)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol cristalino - Google Patents
(2s)-3-[(3s,4s)-3-[(1r)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol cristalinoInfo
- Publication number
- BR112017003010A2 BR112017003010A2 BR112017003010A BR112017003010A BR112017003010A2 BR 112017003010 A2 BR112017003010 A2 BR 112017003010A2 BR 112017003010 A BR112017003010 A BR 112017003010A BR 112017003010 A BR112017003010 A BR 112017003010A BR 112017003010 A2 BR112017003010 A2 BR 112017003010A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxopropane
- methylpyrrolidin
- azetidin
- methylpyridin
- oxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
a presente invenção refere-se a (2s)-3-[(3s,4s)-3-[(1r)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol cristalino, e composições farmacêuticas do mesmo. a presente invenção refere-se adicionalmente a métodos de uso deste composto para tratar bexiga hiperativa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/085925 WO2016033776A1 (en) | 2014-09-04 | 2014-09-04 | Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol |
PCT/US2015/047415 WO2016036596A1 (en) | 2014-09-04 | 2015-08-28 | Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017003010A2 true BR112017003010A2 (pt) | 2017-12-12 |
Family
ID=54073019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017003010A BR112017003010A2 (pt) | 2014-09-04 | 2015-08-28 | (2s)-3-[(3s,4s)-3-[(1r)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol cristalino |
Country Status (26)
Country | Link |
---|---|
US (1) | US10065942B2 (pt) |
EP (1) | EP3189044B1 (pt) |
JP (1) | JP6364545B2 (pt) |
KR (1) | KR20170038884A (pt) |
CN (1) | CN107001327B (pt) |
AP (1) | AP2017009774A0 (pt) |
AU (1) | AU2015312229B2 (pt) |
BR (1) | BR112017003010A2 (pt) |
CA (1) | CA2956517A1 (pt) |
CL (1) | CL2017000467A1 (pt) |
CO (1) | CO2017001097A2 (pt) |
CR (1) | CR20170051A (pt) |
DO (1) | DOP2017000037A (pt) |
EA (1) | EA031089B1 (pt) |
EC (1) | ECSP17013015A (pt) |
ES (1) | ES2688167T3 (pt) |
IL (1) | IL250356A0 (pt) |
MA (1) | MA40606A (pt) |
MX (1) | MX2017002688A (pt) |
NZ (1) | NZ728359A (pt) |
PE (1) | PE20170442A1 (pt) |
PH (1) | PH12017500400A1 (pt) |
SG (1) | SG11201701608RA (pt) |
TN (1) | TN2017000045A1 (pt) |
TW (1) | TWI570119B (pt) |
WO (2) | WO2016033776A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR101696A1 (es) * | 2014-09-12 | 2017-01-04 | Lilly Co Eli | Compuestos de azetidiniloxifenilpirrolidina |
CN112409333B (zh) * | 2019-08-23 | 2024-06-14 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6258833B1 (en) * | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
EP1802615A1 (en) * | 2004-10-20 | 2007-07-04 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
JP2009509984A (ja) | 2005-09-29 | 2009-03-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 泌尿器系障害の処置用のpde阻害剤およびそれらの組合せ |
TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
TWI617553B (zh) * | 2013-03-13 | 2018-03-11 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
-
2014
- 2014-09-04 WO PCT/CN2014/085925 patent/WO2016033776A1/en active Application Filing
-
2015
- 2015-08-20 TW TW104127201A patent/TWI570119B/zh not_active IP Right Cessation
- 2015-08-28 CR CR20170051A patent/CR20170051A/es unknown
- 2015-08-28 EP EP15762875.1A patent/EP3189044B1/en active Active
- 2015-08-28 CN CN201580047664.6A patent/CN107001327B/zh active Active
- 2015-08-28 TN TN2017000045A patent/TN2017000045A1/en unknown
- 2015-08-28 MA MA040606A patent/MA40606A/fr unknown
- 2015-08-28 CA CA2956517A patent/CA2956517A1/en not_active Abandoned
- 2015-08-28 PE PE2017000107A patent/PE20170442A1/es unknown
- 2015-08-28 BR BR112017003010A patent/BR112017003010A2/pt not_active Application Discontinuation
- 2015-08-28 MX MX2017002688A patent/MX2017002688A/es unknown
- 2015-08-28 EA EA201790143A patent/EA031089B1/ru not_active IP Right Cessation
- 2015-08-28 SG SG11201701608RA patent/SG11201701608RA/en unknown
- 2015-08-28 AU AU2015312229A patent/AU2015312229B2/en not_active Ceased
- 2015-08-28 ES ES15762875.1T patent/ES2688167T3/es active Active
- 2015-08-28 AP AP2017009774A patent/AP2017009774A0/en unknown
- 2015-08-28 US US15/505,740 patent/US10065942B2/en active Active
- 2015-08-28 KR KR1020177005724A patent/KR20170038884A/ko active IP Right Grant
- 2015-08-28 WO PCT/US2015/047415 patent/WO2016036596A1/en active Application Filing
- 2015-08-28 NZ NZ728359A patent/NZ728359A/en not_active IP Right Cessation
- 2015-08-28 JP JP2017512825A patent/JP6364545B2/ja active Active
-
2017
- 2017-01-30 IL IL250356A patent/IL250356A0/en unknown
- 2017-02-03 DO DO2017000037A patent/DOP2017000037A/es unknown
- 2017-02-06 CO CONC2017/0001097A patent/CO2017001097A2/es unknown
- 2017-02-27 CL CL2017000467A patent/CL2017000467A1/es unknown
- 2017-03-02 EC ECIEPI201713015A patent/ECSP17013015A/es unknown
- 2017-03-03 PH PH12017500400A patent/PH12017500400A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000566A1 (es) | Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589) | |
PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
MX2020004504A (es) | Derivados de fenoximetilo. | |
DK3154959T3 (da) | 1-((3s,4r)-4-(3-fluorphenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urinstof som en trka-kinaseinhibitor | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
MX2018001430A (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
SI3145934T1 (sl) | Substituirane spojine -6,8-dioksabiciklo(3.2.1)oktan-2,3-diol kot zdravila, ki delujejo na ASGPR | |
EA201691799A1 (ru) | Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) | |
IN2015DN00960A (pt) | ||
BR112013031493A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto. | |
AU2015352440B2 (en) | Compounds | |
AU2015339087B2 (en) | Trifluoromethyl alcohols as modulators of RORyt | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
PH12017500447A1 (en) | Triazole compounds as t-type calcium channel blockers | |
WO2012112548A3 (en) | Firmocidin, an antimicrobial molecule produced by staphylococcus epidermidis | |
NZ722412A (en) | Methods of preparing a hydrochloride salt of (1r,2r,5r)-5-amino-2-methylcyclohexanol | |
CL2016001488A1 (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
MX2016016840A (es) | Nuevas pirazolil-triazolil-piridinas como agentes plaguicidas. | |
DOP2017000037A (es) | (2S)-3-[(3S,4S)-3-[(1R)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol Cristalino | |
EP3578545A4 (en) | PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS | |
ZA201700527B (en) | Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl) -3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol | |
EA201892406A1 (ru) | Способ получения гербицидных пиридинилимидазолоновых соединений | |
PH12018500406A1 (en) | Bicyclic compounds as atx inhibitors | |
PH12018500407A1 (en) | New bicyclic compounds as dual atx/ca inhibitors | |
AU2015904156A0 (en) | Optical transistor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |